Literature DB >> 29709067

The pathogenicity of IL-33 on steroid-resistant eosinophilic inflammation via the activation of memory-type ST2+ CD4+ T cells.

Kiyoshi Hirahara1,2, Naoko Mato3, Koichi Hagiwara3, Toshinori Nakayama1.   

Abstract

The lungs are the primary organs of the respiratory system in many animals and have unique epithelial barrier systems to protect the host from continuous invasion of various harmful particles, such as viruses and bacteria. IL-33, a member of the IL-1 family of cytokines, is released from epithelial cells in the mucosal organs and drives the type 2 immune response by activating a number of immune cells in cases of helminth infection. However, IL-33 derived from epithelial cells also causes various allergic diseases via the activation of ST2-positive immune cells, including memory-type (CD62Llow CD44hi ) ST2+ CD4+ T cells in the lung. Recent studies have revealed that the type 2 inflammation induced by IL-33 is steroid resistant. Steroid resistance causes severe chronic inflammatory diseases, such as intractable asthma. In this review, we will discuss the impact of ST2+ CD4+ T cells on shaping the pathology of IL-33-induced eosinophilic inflammation. We will also highlight the mechanism underlying steroid resistance in eosinophilic pneumonia. A better understanding of the cellular and molecular mechanisms underlying steroid resistance is crucial for the development of new therapeutic strategies for intractable allergic diseases. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  eosinophilic pneumonia; epithelial cytokine; iBALT; pathogenic Th2

Mesh:

Substances:

Year:  2018        PMID: 29709067     DOI: 10.1002/JLB.MR1117-456R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

Review 1.  IL33: Roles in Allergic Inflammation and Therapeutic Perspectives.

Authors:  Ben C L Chan; Christopher W K Lam; Lai-Shan Tam; Chun K Wong
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

Review 2.  Marine-Derived Compounds for the Potential Treatment of Glucocorticoid Resistance in Severe Asthma.

Authors:  Cristina Mihaela Ghiciuc; Andrei Gheorghe Vicovan; Celina Silvia Stafie; Sabina Antonela Antoniu; Paraschiva Postolache
Journal:  Mar Drugs       Date:  2021-10-20       Impact factor: 5.118

Review 3.  Immunobiology of Steroid-Unresponsive Severe Asthma.

Authors:  Courtney Lynn Marshall; Kosovare Hasani; Neeloffer Mookherjee
Journal:  Front Allergy       Date:  2021-08-27

Review 4.  T cells in severe childhood asthma.

Authors:  Alberta G A Paul; Lyndsey M Muehling; Jacob D Eccles; Judith A Woodfolk
Journal:  Clin Exp Allergy       Date:  2019-04-04       Impact factor: 5.018

5.  Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure.

Authors:  Jehan W Alladina; Francesca L Giacona; Emma B White; Kelsey L Brait; Elizabeth A Abe; Sam A Michelhaugh; Kathryn A Hibbert; James L Januzzi; B Taylor Thompson; Josalyn L Cho; Benjamin D Medoff
Journal:  Crit Care Explor       Date:  2021-06-29

6.  The Role of Pro-Inflammatory and Regulatory Signaling by IL-33 in the Brain and Liver: A Focused Systematic Review of Mouse and Human Data and Risk of Bias Assessment of the Literature.

Authors:  Nika Zharichenko; Dolores B Njoku
Journal:  Int J Mol Sci       Date:  2020-05-30       Impact factor: 5.923

Review 7.  Why do some asthma patients respond poorly to glucocorticoid therapy?

Authors:  Ishbel Henderson; Elisabetta Caiazzo; Charles McSharry; Tomasz J Guzik; Pasquale Maffia
Journal:  Pharmacol Res       Date:  2020-09-08       Impact factor: 7.658

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.